ET for premenopausal breast cancer patients typically includes tamoxifen alone or a gonadotropin-releasing hormone (GnRH) agonist as ovarian function suppression (OFS) therapy in combination with ET, depending on various factors as outlined above [11,14,15,16,17,18,19]. This evidence concerns the gene GNRH1 and breast cancer.